Lymphoma Treatment Offers Hope for AIDS Patients

Results of a clinical trial out of the City of Hope Medical Centre in Duarte, California suggest that a new and effective therapy may be on the way for AIDS patients.



In the trial, five AIDS patients who were suffering from AIDS-related lymphoma (lymphomas are a frequent cause of death in AIDS patients) received a rather spiffy bone marrow transplant. Here’s how it worked:



Scientists first isolate the genes that curtail the spread of the HIV virus in the body. After introducing these genes into human donor stem cells in the lab, they transplant the whole package into the bone marrow. Those stem cells grow and make new white blood cells, ones that are HIV resistant.



It’s an example of stem-cell genetic modification, using specific genes to go after specific issues in the bone marrow.



Of course, bone marrow transplants are common in treating lymphoma. They’re also very risky. Before a patient can be given donor marrow, they are first exposed to medications that eliminate their own bone marrow.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap